


Dorset CCG Primary Care DVT Pathway for NOAC

Refer to further information e.g. NOAC contraindications, dose reductions in:

- The summary of product characteristics (SPC) for the relevant NOAC available at <http://www.medicines.org.uk/emc/>
- Dorset CCG Shared Care guidelines for Rivaroxaban and Dabigatran for treatment of DVT and PE
- NICE TA261 - Rivaroxaban for the treatment of DVT and prevention of recurrent DVT and PE (2012)



*NOAC prescribing guidance

Wells Score >2 and/or positive D-dimer with no clinical contraindications for NOAC:

Commence Rivaroxaban 15mg BD x 7 days

DVT excluded by ultrasound scan:

Stop Rivaroxaban

DVT confirmed by ultrasound scan:

Continue Rivaroxaban 15mg x 14 days (to complete 21 days of initial dose) followed by Rivaroxaban 20mg daily for minimum of 3 months (dose is dependent upon renal function see SPC) <http://www.medicines.org.uk/emc/>

****3 month review:**

Stop Rivaroxaban or continue dependent on DVT cause i.e. provoked or unprovoked and ongoing risk factors

Note All patients on NOAC to carry yellow anticoagulation alert card

Anti-embolic stockings not required for below knee DVT. (Should be fitted by someone trained with awareness of contraindications)

DVT Clinical lead

Dr Jason Mainwaring, Consultant Haematologist for advice and guidance re complex patients Jason.Mainwaring@rbch.nhs.uk